Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Assessment of hepatotoxic liabilities by transcript profiling.

Stefan Ruepp1, Franziska Boess, Laura Suter

  • 1F. Hoffmann-La Roche Ltd., PRBN-S (90/5.18), CH-4070 Basel, Switzerland. stefan.ruepp@roche.com

Toxicology and Applied Pharmacology
|July 2, 2005
PubMed
Summary

This study developed a toxicogenomics model using rat data to predict liver toxicity in novel compounds. The model successfully identified hepatotoxic liabilities early, even without pathological signs, aiding drug safety assessments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microsurgical outcomes of free flaps in patients with sickle cell trait: A case series.

JPRAS open·2026
Same author

Beyond Body Mass Index: Using Abdominal Wall Thickness to Guide Patient Selection for Deep Inferior Epigastric Perforator Flap Breast Reconstruction.

Journal of reconstructive microsurgery·2026
Same author

Patient-Centric First-in-Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T-Cell Engagers in Multiple Myeloma.

Clinical pharmacology and therapeutics·2026
Same author

Transient prophylactic immunosuppression with abatacept or dasatinib prevents immune responses in AAV gene transfer.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Defining the bellwether procedures and processes for global trauma care: an international Delphi study.

BMJ global health·2026
Same author

Protocol for evaluation of Movember's scaling what works grant funding program: Supporting the delivery of mental health interventions for men & boys in Australia, Canada and the United Kingdom.

PloS one·2026

Area of Science:

  • Toxicology
  • Genomics
  • Pharmacology

Background:

  • Developing predictive models for compound toxicity is crucial for drug safety.
  • Toxicogenomics offers a powerful approach to assess potential adverse effects early in development.

Purpose of the Study:

  • To create a toxicogenomics reference database for assessing novel compounds.
  • To develop a predictive model for identifying hepatotoxic liabilities using transcript profiles.
  • To validate the model's accuracy and early detection capabilities.

Main Methods:

  • Male Wistar rats were treated with model compounds and controls.
  • Histopathology and clinical chemistry data anchored transcript profiles to toxicological endpoints.
  • Supervised learning (Support Vector Machines) generated a predictive classification model.

Related Experiment Videos

Main Results:

  • The toxicogenomics model successfully discriminated between steatotic and non-hepatotoxic compounds.
  • Hepatotoxic liabilities were identified early, sometimes before pathological findings.
  • In vitro and in vivo studies confirmed the model's predictive accuracy.
  • Transcript profiles indicated toxicologically relevant changes earlier than traditional methods.

Conclusions:

  • Toxicogenomics is a valuable tool for early adverse effect alerts and mechanistic hypothesis generation.
  • The developed predictive model aids in assessing potential hepatotoxic liability of novel compounds.
  • This approach enhances the efficiency and reliability of preclinical safety evaluations.